News & Events

Redbiotec is pleased to announce that the international search report of our PCT patent application covering our CMV program has  been very positive. All of Redbiotec’s 18 claims have been given a “yes” for novelty, a “yes” for inventive step and a “yes” for industrial applicability. The patent application will be published end of April 2014.

Redbiotec is pleased to announce that is has entered into a collaboration with GSK vaccines. In a feasibility study GSK will apply Redbiotec’s assets and its proprietary technology platform rePAX® to an undisclosed program.

Redbiotec is one of the partners who were granted the Edufluvac project in the frame of the EU FP7-HEALTH.2013.2.3.0-1 package (EU contribution €4.6M). The project aims towards “universal” influenza vaccines, providing longer-lasting and broader protection against multiple strains of the virus, ultimately protecting
the general population from seasonal and pandemic influenza. [Press release]

San Francisco, CA, and Zurich, Switzerland.
Redbiotec and TeselaGen have announced a joint venture to build a scalable, integrated, rapid design and rapid prototyping infrastructure for the creation of a library for Herpesvirus vaccine development. This library will enable new concepts for vaccines against Herpesviruses and will enable the optimization and improvement of new and existing vaccine candidates. [Press release]

Redbiotec AG announces today the appointment of Prof. Dr. Bodo Plachter, Institute of Virology, Universitätsmedizin (University Medical Centre) Mainz, to Redbiotec’s team. Prof. Plachter is one of the world’s leading scientists studying the Cytomegalovirus (CMV). His work includes prophylactic and therapeutic vaccine development against Herpesviruses/CMV.